Effectiveness of imepitoin for the control of anxiety and fear associated with noise phobia in dogs by Engel, Odilio et al.
For Peer Review
Imepitoin effectively controls anxiety and fear associated 
with noise phobia in dogs.
Journal: Journal of Veterinary Internal Medicine
Manuscript ID JVIM-19-076.R3
Wiley - Manuscript type: Standard Article
Keywords (You can enter any 
word desired, do not have to 
use from the list):
Behavior, Clinical Trials, Imepitoin, Noise Phobia
 
Journal of Veterinary Internal Medicine
For Peer Review
Imepitoin is effective in Noise Phobia. Page 1 of 24
1 Abstract
2 Background: Noise phobia is a common behavior problem in dogs with limited treatment 
3 options.
4 Objective: The aim was to evaluate the efficacy and safety of imepitoin in comparison to placebo 
5 for the control of anxiety and fear associated with noise phobia in dogs. 
6 Methods: This placebo-controlled, randomized, double-blinded, clinical trial used a predictable 
7 noise event as eliciting context, the traditional New Year’s Eve fireworks in Germany and the 
8 Netherlands. Owners began treatment two days before the anticipated noise event with twice 
9 daily administration of either imepitoin 30 mg/kg body weight or placebo for three consecutive 
10 days. On New Year’s Eve, owners noted their observations of their dog’s fear and anxiety 
11 behavior at fixed time points (i.e. 16:00 h, 22:00 h, 0:20 h, 1:00 h). In addition, they scored the 
12 overall treatment effect on the following day.  
13 Results: Amongst 238 privately owned dogs, those treated with imepitoin showed significantly 
14 reduced signs of anxiety and fear during New Year’s Eve’s fireworks compared to placebo 
15 treated dogs.  A significantly higher proportion of owners reported a good or excellent overall 
16 treatment effect in the imepitoin group compared to placebo (odds ratio 4.689 
17 (95% CI: 2.79, 7.89) p < .0001). In the 16-item owner report of fear and anxiety signs, fear and 
18 anxiety behaviors were significantly reduced under imepitoin treatment compared to placebo 
19 (delta -6.1 scoring points; p < .0001). 
20 Conclusion: Imepitoin represents an effective option for the control of fear and anxiety 
21 associated with noise phobia in dogs.
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22 Introduction
23 Fear responses to noises are quite common in dogs with a prevalence of up to 49% 1, and a 
24 proportion showing non-graded extreme responses to noises indicative of a phobia 2. Exposure to 
25 a phobic stimulus almost invariably provokes an immediate behavioral response with 
26 concomitant physiological signs of autonomic arousal 2. A phobia in animals involves a marked, 
27 persistent, and excessive fear of clearly discernible circumscribed objects or situations. The term 
28 phobia is derived from human psychiatry, where it describes an irrational fear, and it is mainly 
29 used to create a qualitatively distinct category for the purposes of psychiatric diagnosis, but there 
30 is some debate over whether this term should be applied to animals. Whilst the terms “noise 
31 sensitivity”, “noise aversion” or “fear response to noise” are used in the veterinary behavior 
32 literature, “noise phobia” is probably the most widely used term to describe the clinical complaint 
33 and is used in this paper, defined as overly anxious reactions by dogs to specific sounds. This 
34 reaction is often stressful for the owners and a welfare issue for the affected individual. 
35 Diagnostically, it is useful to separate phobias from normal temporary responses which should be 
36 of less concern, but the point “at which a fear becomes a phobia is unknown” 3; indeed all data to 
37 date indicate that the behavioral response to an aversive event or situation is dimensional in 
38 nature, and thus that the problem exists as a spectrum which includes normality. Even if the 
39 paradigm used for conceptualizing problems in veterinary behavioral medicine places noise 
40 phobia within the context of a normal (albeit undesirable and potentially extreme) emotional 
41 response rather than an artificially constructed medical category, it does not negate the value of 
42 psychopharmacological interventions 4, which may protect the dogs’ well-being 5 or enable 
43 behavioral management 6.  
44 Benzodiazepines , targeting GABAA (γ-aminobutyric acid, type A) receptors, are commonly used 
45 to manage fear and anxiety-related conditions. However, development of drug dependence, loss 
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46 of efficacy (tolerance) and adverse drug effects limit their use 7. New approaches to improve the 
47 safety profile have been the focus of research for some time, looking mainly on GABAA subtype 
48 specific molecules or partial agonists 7. Imepitoin acts centrally as a partial agonist at the 
49 benzodiazepine-binding site of the GABAA-receptor with low affinity, potentiating neuronal 
50 inhibition resulting in anxiolytic and anticonvulsant effects 8. It is in veterinary use in many 
51 countries for the treatment of idiopathic epilepsy and is well tolerated. In standard rodent models, 
52 imepitoin showed similar anxiolytic activities to benzodiazepines 9 and a recent case series has 
53 suggested it may be useful for managing fear and anxiety-related conditions in dogs 10. Therefore, 
54 the aim of this study was to determine the effectiveness and safety of imepitoin in comparison to 
55 placebo for reducing anxiety and fear associated with noise phobia in dogs. 
56 Methods
57 Study design
58 The study was conducted as a multicenter, randomized, double-blinded, placebo-controlled, 
59 clinical field trial according to Good Clinical Practice (GCP) guidelines with client-owned 
60 animals. The study design used a predictable noise event as the eliciting context: the traditional 
61 New Year’s Eve fireworks in Germany and the Netherlands on December 31st 2016. All study 
62 procedures were timed around this event (Figure 1). Twenty-one Study Sites participated in this 
63 study, in various geographic areas in Germany (17 sites) and the Netherlands (4 sites). Most 
64 practices were located in urban areas. In total, 251 dogs were included and 238 were treated 
65 either with imepitoin or placebo in a ratio of approximately 1:1. During the evaluation phase of 
66 the study, all animals remained in their familiar surroundings. The  two primary variables for 
67 efficacy evaluation were  the owner assessment of overall treatment effect and a detailed owner 
68 assessment of behavioural responses. 
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69 The conduct of the study was ethically approved prior to study start by the relevant authorities in 
70 Germany and the Netherlands.
71 There were three visits at the vet for the owner (Figure 1). At inclusion visit, a physical 
72 examination, evaluation of eligibility based inclusion and exclusion criteria (see below) and 
73 blood sampling took place. The medication and the diary for the owner’s observations was 
74 dispensed at a separate dispensing visit. A physical examination and the collection of the diary 
75 concluded the study at the end of study visit.
76 Inclusion and Exclusion Criteria
77 All dogs enrolled in this study were client owned, and lived in Germany or the Netherlands. The 
78 dog’s owner or authorized agent signed an Informed Consent at the inclusion visit before study 
79 procedures. Dogs were recruited at veterinary practices during routine visits or after personal 
80 contact due to previous visits for this problem.
81 Dogs of any breed or mixedbreed and of either gender that weighed greater than or equal to two 
82 kilograms were eligible to be screened. The diagnosis of noise phobia was based on ruling out 
83 medical causes through routine veterinary clinical examination alongside a history of signs of 
84 noise phobia with a score above 30 in the Lincoln Sound-Sensitivity Scale (LSSS) 11 and 5 
85 confirmatory questions to exclude other anxiety problems. 
86  Patient displayed fear responses to specific, identifiable firework noises in previous 
87 year(s) without medical treatment
88  The fear and anxiety response is reliably elicited upon exposure to loud, explosive noises 
89 (e.g. fireworks, thunderstorms, gunshots, etc.) 
90  The fear and anxiety responses occur in the home (and may also  occur when out)
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91  Fear and anxiety responses occur while the owner or another familiar person is present
92  The fear/anxietyis not generalized to the extent that the eliciting cues are too numerous to 
93 be identifiable and the dog rarely appears relaxed
94 The cut-off point in the LSSS of 30 captures the essence of the definition of noise phobia used in 
95 here, i.e. that it is an “excessive fear or anxiety of a sound”. Excessive can be considered to refer 
96 to either the severity of signs (i.e. at least two signs with most intense form [score 5] every time 
97 the noise was heard [score 3]) or the number of signs (i.e. all 16 signs occur frequently [score 2] 
98 in the lowest intensity [score 1]). 
99 In addition, dogs had to be healthy or with a stable systemic disease, considered to be pain-free 
100 for at least two weeks prior to inclusion (no painful condition or stable under pain management 
101 including medication) and have been with the current owner for at least one year. The owner had 
102 to agree that either he/she or another person familiar with the dog would be with the dog on New 
103 Year’s Eve, and this person had observed a fear response in the dogs during previous fireworks. 
104 Dogs suffering from generalized fears, as well as dogs on treatment with behavior modifying 
105 drugs in the previous two months were excluded. Sedatives were permitted for a single occasion 
106 and for purposes not related to behavior problems (e.g., diazepam as a preanesthetic) up to two 
107 weeks before treatment start. Known epilepsy or treatment with imepitoin during the last 5 
108 months, as well as dogs that had been treated to diminish signs of noise phobia in the past 12 
109 months, were excluded. Dogs with a history of, or concomitant disease, such as severely impaired 
110 hepatic function, severe renal or severe cardiovascular disorders were not included. Significant 
111 family-related risk factors affecting risk to individuals from the dog’s behavior (e.g. dogs that had 
112 bitten people in the past; toddlers in the home in the case of aggressive behavior towards people; 
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113 aggression between dogs within home; or dogs that showed other aggressive tendencies of 
114 concern in the past) also led to exclusion. 
115 An enrolled animal was removed from further participation in the study if the owner withdrew 
116 their consent, if the owner was non-compliant with the study procedures, if the temperament of 
117 the dog prohibited administration of the study drug, if there was a change in pain medication, if 
118 study medication was not administered, if the owner indicated that the dog was not exposed to 
119 firework noises on New Year’s Eve, or if an adverse event or development of concomitant 
120 disease prohibited further participation. Treatment with anxiolytic, psychotropic, sedative, other 
121 behavior modifying drugs or homeopathic or natural remedies intended to reduce stress or 
122 anxiety was prohibited during the study. 
123 The owners are provided with advice complementary to the treatment provided, to help to 
124 minimize the stress for the dog and to avoid counterproductive measures by the owner that might 
125 bias outcome. These statemets were not to punish the dog when scared, not to overly fuss or try 
126 to reassure the dog when scared, to ignore the noises as owner and to keep the dog in a safe and 
127 secure environment to avoid escaping. No other advice on environmental or behavior 
128 modification was provided.
129 Trial Medication
130 Dogs received either imepitoin at a dose of approximately 30 mg/kg twice daily, or visually 
131 identical placebo tablets. Dogs were administered the appropriate amount of tablets orally twice 
132 daily at approximately 12 hours intervals starting two days before the day of anticipated noise 
133 event. The first administration was in the morning of 29th December, and the last administration 
134 was in the evening of 31st December (ideally between 18:00 and 20:00 h). 
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135 Assessment of Fear and Anxiety related behaviors
136 The primary efficacy assessment of the study aimed to show if there was superiority of imepitoin 
137 over the placebo. To assess this, two co-primary efficacy variables were used.
138 The first primary efficacy variable was the owner overall assessment of the treatment effect on 
139 the fear and anxiety behavior of the dog in response to fireworks on New Year’s Eve, using a 5-
140 point ordinal score (Table 1). This assessment was done on January 1st, not earlier than 6:00 am. 
141 This timepoint ensured a retrospective judgment for the whole duration of the noise event. 
142 The second co-primary efficacy variable was based on a detailed 16-item owner questionnaire, 
143 reporting the dog´s fear and anxiety signs. This questionnaire was modified from the Lincoln 
144 Sound-Sensitivity Scale (LSSS,) 11 by adopting the behaviors and their intensity scoring, but not 
145 their frequency (as the current questionnaire was assessing response to a specific event, rather 
146 than over an extended period). Following the model developed in the LSSS, the intensities of 16 
147 behaviors during the 15 minutes prior to the assessment were classified on an ordinal  scale from 
148 zero (not present) to one (small amount) through five (extensive amount) and added up to a total 
149 sum score (Table 2). The owners were asked to complete the score 4 days before New Year’ Eve 
150 (i.e. on December 27th) for baseline and at 16:00 h, 22:00 h on New Year’s Eve and at 0:20 h and 
151 1:00 h on New Year’s Day. In addition, they indicated whether fireworks were present during the 
152 last 20 minutes prior to each assessment.
153 Statistics
154 Randomization was based on blocks of 2 using a pseudo random number generator so that the 
155 resulting assignment of medication numbers to the treatment group was both reproducible and 
156 non-predictable. Each investigator received a set of medication numbers and assigned the 
157 medication numbers in ascending order to the included dogs.
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158 The analysis of the co-primary variables was performed on the Full Analysis Set (FAS). The FAS 
159 comprised of all dogs which were randomized to the treatment groups, received at least one dose 
160 of study medication, fulfilled major entry criteria, and completed at least the evaluations 
161 necessary for the analysis of the co-primary efficacy variables. This population followed the 
162 Intention to Treat principle (Figure 2).  Per Protocol Populations were defined, where patients 
163 with major protocol deviations such as insufficient treatment compliance or administration of 
164 other behavior modifying drugs were excluded. For the first co-primary variable, a generalized 
165 linear model with cumulative logit link was used to estimate and test the (cumulative) odds ratio 
166 of imepitoin vs. placebo utilizing the GLIMMIX procedure of SAS (SAS Institute Inc., Cary, NC, 
167 USA). The model included treatment as a fixed effect and site and treatment-by-site as random 
168 effects. The second co-primary variable was analyzed using a mixed model to estimate and test 
169 the difference in mean fear and anxiety behavior scores utilizing the MIXED procedure of SAS, 
170 with treatment, time point, and time point-by-treatment interaction as fixed effects, subject, site 
171 and site-by-treatment interaction as random effects, and baseline as covariate. Safety was 
172 analyzed for all dogs who received at least one dose of treatment (see Figure 2).
173 Results
174 Demographics
175 The demographic data and baseline characteristics were well balanced between the two treatment 
176 groups in all populations (Table 3). More than half of the patients were female (60.5% females; 
177 39.5% males), and the majority of dogs (81.9%) were neutered or spayed. There was no obvious 
178 overrepresentation of any breed, and most dogs were of mixed breeds (39.1%). 
179 The proportions of patients taking concomitant therapy were similar in both treatment groups 
180 (imepitoin 13.5%; placebo 18.0%). There was no specific treatment category predominantly 
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181 represented, and two animals received prohibited drugs for nervous system disorders during the 
182 trial (psycholeptics: benzodiazepine; phenothiazine with aliphatic side-chain). In line with 
183 hypothyroidism being the most frequently reported disease at baseline, thyroid preparations were 
184 the most commonly reported concomitant treatment (5.8%; imepitoin 3.8%; placebo 7.4%). 
185 At inclusion, dogs presented with noise phobia  defined here ans “excessive fear or anxietyof a 
186 sound”, as indicated by a high score in the Lincoln Sound Sensitivity Scale in both groups (Table 
187 3). In detail, 85% of dogs recruited showed at least one behaviour at its most extreme (i.e. score 5 
188 in intensity) and the minimum number of signs shown by any dog recruited in this study was 4 
189 (mode = 9 signs with score > 0). The most common signs were shaking or trembling (95.1%), 
190 cowering (94.2%) and hiding (93.8%). Hiding is clearly indicative of the response interfering 
191 with the dog’s ability to function normally in the home.
192 Treatment Compliance
193 Compliance was generally high in both treatment groups, with 87.5% of imepitoin-treated dogs 
194 and 90.2% of placebo-treated dogs receiving all 6 administrations. Some owners continued 
195 administrations after 31st December (3 imepitoin, 4 placebo) due to ongoing occasional fireworks, 
196 so these dogs received in total 7 to 10 administrations. In 7 cases (5 imepitoin; 2 placebo), the 
197 investigator lowered the daily dose due to occurrence of ataxia. 
198 Efficacy
199 Both co-primary endpoints, the owner´s overall assessment as well as their assessment of fear and 
200 anxiety behaviors, demonstrated efficacy for the imepitoin group at high thresholds of statistical 
201 significance. 
202 The owner assessment of the overall treatment effect (recorded the day after the noise event -i.e. 
203 1st January) showed a significantly higher proportion of owners reporting a good or excellent 
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204 treatment effect in the imepitoin group compared to placebo (Figure 3). A cumulative odds ratio 
205 of 4.689 (95% CI (2.79, 7.89) with a p-value < .0001 indicates that the odds for a favorable 
206 treatment assessment were four and a half times higher for imepitoin compared to placebo. In the 
207 16-item modified LSSS owner questionnaire, fear and anxiety behaviors were found to be 
208 significantly reduced for imepitoin vs. placebo by a delta of -6.1 scoring points (p < .0001). This 
209 achievement must be compared to the average fear and anxiety increase from baseline in 
210 untreated (placebo) dogs, which reaches an amplitude of 17.97 = 24.88  - 6.91 at the peak time 
211 point 0:20h (amplitude = mean score at 0:20 h minus mean score at baseline; see Figure 4) .  Both 
212 treatment groups exhibited a characteristic progression of the fear and anxiety level towards 
213 midnight, which was followed by a gradual decline afterwards (Figure 4). Fear and anxiety 
214 behaviors in the imepitoin treated dogs were reduced compared to placebo at each time point. 
215 To compare the efficacy at the highest intensity of fireworks, fear and anxiety scores during or 
216 immediately after the fireworks at time point 0:20 h were compared between treatment groups as 
217 a secondary variable. Significantly higher score values were recorded for the placebo group than 
218 for the imepitoin group (24.9 (SD 13.1)  for placebo vs. 16.6  (SD 11.6) for imepitoin; 
219 p < 0.0001). This statement holds true if the increase from the baseline score is considered 
220 instead. This is also verified by the data of the sub-fraction of animals who did no longer 
221 experience fireworks at the time point 1:00h: In the absence of fireworks, the fear and anxiety 
222 level for both treatment groups broadly went down and the difference between the treatment 
223 groups disappeared (data not shown). 
224 The time point when owner assessed that the dog could be left alone after midnight was analyzed 
225 as a secondary variable. Owners believed that they could leave their dog alone on average 162 
226 min ~ 2:40h  (SD 133 min) and 203 min ~ 3:22h (SD 210 min) after midnight, in the imepitoin 
Page 10 of 29Journal of Veterinary Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Imepitoin is effective in Noise Phobia. Page 11 of 24
227 treated group and in the placebo group, respectively. The difference was not statistically 
228 significant.  A notable proportion of owners in both treatment groups stated that, in principle, 
229 they would never leave their dog alone at New Year’s Eve, and so did not answer this question 
230 (15.4% in imepitoin group, 23% in placebo group). Therefore, this parameter might be of limited 
231 reliability.
232 The robustness analyses based on the Per Protocol Population confirmed all above mentioned 
233 efficacy results (Supplementary Material).
234 Safety
235 Imepitoin was well tolerated with no serious adverse events recorded in this trial (a serious 
236 adverse event was defined as an unfavorable observation, which results in death or life-
237 threatening conditions, persistent or significant disability, abortion or birth defects or requires 
238 professional intervention). Reported adverse events were mostly mild and transient, and included 
239 ataxia, increased appetite, lethargy, emesis, hyperactivity and somnolence, all of which occurred 
240 at a higher frequency in the imepitoin than in the placebo group (Table 4). All other adverse 
241 events occurred either in similar frequencies as in the placebo group or were reported only in 
242 very few cases (≤ 2.5%).
243 Transient ataxia was the most commonly reported adverse event, affecting 35.1% of the 
244 imepitoin treated cases, starting on the first day of treatment, mostly between 30 minutes and 4 
245 hours after first drug administration.  It resolved exponentially under continuous treatment, 
246 within a day  in  51.2% and within two days in 24.4% of cases (Figure 5). Occurrence of ataxia 
247 was not overtly associated with specific demographic factors and did not appear to affect the 
248 perception of the treatment effect by the owner.
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249 Discussion
250 While noise phobia is most frequently associated with fireworks, it is more than just a seasonal or 
251 sporadic issue, as affected dogs often also react to a range of other noises such as thunder or 
252 gunshots 2,12. While some dogs with noise phobia respond only to certain sporadically occurring 
253 noises, others have phobias against many noises that may occur year round or to other, less 
254 salient, noises, such as traffic and TV noises 1. Noise phobia may also represent one of several 
255 expressions of a wider underlying anxiety problem 12. Accordingly, treatment approaches should 
256 be tailored to the individual patient’s problem, and may consist of short acute pharmaceutical 
257 interventions for occasional but predictably occurring events causing fear and anxiety or long-
258 term psychoactive medication either alone or in combination with a short-acting anxiolytic when 
259 needed 12. In all cases, behavior therapy, preferably by a specialist, would be ideal in combination 
260 with psychoactive drugs to provide the best long-term effect 2.
261 Since there is strong evidence that dogs with noise phobia generalize fear of one type of loud 
262 sudden noise to others 1,13, New Year fireworks provide a good standardization of the eliciting 
263 context for noise phobia more generally. Thus, this study provides evidence that imepitoin is 
264 effective in reducing signs of anxiety and fear associated with noise phobia in dogs. 
265 Placebo-controlled trials are considered the best evidence for anxiolytic therapies 14. Currently 
266 only a third of owners with dogs suffering from fear responses to noises seek treatment advice 1, 
267 despite the fact that noise phobia  has negative effects on both health and lifespan of dogs 15,16. 
268 Regarding the dose regimen, we aimed to establish an efficacious blood level of imepitoin at the 
269 initiation of the noise event to preemptively limit the fear and anxiety experience. Since titration 
270 of the dose up to an efficacious level is not possible for sudden noise interventions, the drug was 
271 administered before New Year’s Eve to ensure efficacy. The dose and dosing regimen of 
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272 imepitoin in this study (approximately 30 mg/kg twice daily. starting 2 days before the day of the 
273 anticipated event and continued through the day of the event) was chosen on the basis of our 
274 understanding of both the pharmacokinetic properties 17 and previous studies 10 to maximize the 
275 likely benefit at minimum risk for the population, whilst recognizing that lower doses and/or 
276 shorter pre-treatment times might be sufficient in some dogs. For example, in a laboratory setting, 
277 a single dose of 20 mg imepitoin per kg body weight, administered 135 min before a noise event 
278 has shown anxiolytic properties 9. This is consistent with the observations in this study, where a 
279 reduction in noise phobia response was still demonstrated in the few cases where the dose was 
280 lowered due to adverse events. 
281 Anxiety and fear are difficult to measure, as they are subjective unpleasant feelings resulting in 
282 typical but varied behaviors. As dogs cannot express their feelings, investigations are typically 
283 limited to behavioral observations, which can be done best in familiar environments (i.e. at home, 
284 in kennels or at work). The outcome in this clinical trial was based on rating scales that were 
285 previously established and commonly used in similar  trials on anxiety problems 10,18,19. While 
286 owner reported outcome was shown to deliver reliable and accurate descriptions of dogs’s 
287 fearfulness, possible subjective and emotional inputs by owners are a risk for bias and needs to be 
288 controlled by a proper design of the questionnaires20. It is clearly a limitation of such studies that 
289 questionnaires are difficult to design and up to now there are no validated questionnaires. For 
290 example, in this study we used a 5 point questionnaire to assess the owners impression on the 
291 overall treatment effect. To stimulate the owner to think how the dog would normally react to the 
292 fearful stimulus without treatment, categories with a clear reference to the expected and known 
293 reaction of the dog were linked to “previous year(s) without treatment”. While this might help the 
294 owner to better understand the categories, it also introduces some inconsistency into the 
295 questionnaire. As treatment success was defined as reaching a meaningful benefit in the owner 
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296 assessment of overall treatment effect and in the detailed owner assessment of behavioural 
297 responses using a modified version of the Lincoln Sound Sensitivity Scale, the results in the 
298 questionnaire appear reasonably robust. 
299 The quality of life and well-being of the dog are determined by the emotional and behavioral 
300 consequences of the fear and anxiety problem. In this study, the fear and anxiety scores at 
301 baseline were in the normative range in both treatment groups. Dogs receiving imepitoin 
302 treatment experienced an increase in fear and anxiety score at midnight during the highest 
303 intensity of firework exposure while showing clearly improved reactions at all time points 
304 compared to placebo. These might be considered acceptable “normal” fear responses that do not 
305 pose a practical threat to the animal’s well-being. Importantly, imepitoin-treated dogs returned 
306 almost to their baseline score one hour aft r the highest intensity of fireworks (1h time point). In 
307 comparison, placebo-treated dogs showed elevated fear and anxiety scores throughout New 
308 Year’s Eve, including at the 1hr time point. Additionally, the majority of owners reported a good 
309 or excellent overall treatment effect in dogs treated with imepitoin, being in the same order of 
310 magnitude of owner reported treatment success for treatments like diazepam 21, dexmedetomidine 
311 19 or a combination of fluoxetine, diazepam and behavior modification 22. 
312 In this study, ataxia was the most frequently reported adverse reaction. Drug-induced ataxia is 
313 commonly associated with antiepileptics and benzodiazepines 23. Several studies provide 
314 evidence that certain subunits of the GABAA receptor are responsible for these effects and 
315 individual predisposition to transient ataxia is probably linked to certain point mutations 24,25. In 
316 this study, there was a spontaneous resolution of ataxia with continuation of treatment, in most 
317 cases within 24 to 48 hours. Other less frequently reported mild and transient adverse events, 
318 such as increased appetite, lethargy, emesis and hyperactivity, appear also to be related to 
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319 imepitoin treatment. No withdrawal symptoms, drug tolerance or serious adverse events were 
320 observed after this short treatment period, which were not to be expected based on previous data 8. 
321 The risks with imepitoin, appear less than with benzodiazepines, which can cause, in addition to  
322 adverse events of sedation, ataxia, and increased appetite or agitation 21, a strong potential for 
323 drug dependency, development of tolerance and exhibition of withdrawal symptoms with abrupt 
324 discontinuation 26. Another medication used for this condition, oromucosal dexmedetomidine is 
325 quite well tolerated in dogs at therapeutic doses with adverse events like sedation, vomiting or 
326 urinary incontinence, but overdoses are associated with substantial risk to the animal in addition 
327 to the health risk for individuals administering the drug, necessitating the requirement to wear 
328 gloves. 27 
329 A limitation of this study is the exclusion of dogs with a history of aggression problems. While 
330 anxiety and fear are underlying causes in many cases of canine aggression problems and thus an 
331 anxiolytic treatment might be of benefit, these cases require a much more complex and individual 
332 approach preferably overseen by a specialized veterinarian. This is far beyond the standardized 
333 treatment scheme in this study, so further studies are required for this patient population. 
334 The use of placebo in clinical trials for indications with an effective treatment is an area of some 
335 controversy, since applying placebo exposes patients to potential distress 28. However, the use of 
336 placebo is the gold-standard for ensuring accurate information on the real treatment benefit in the 
337 anticipated clinical use allowing an evidence-based treatment decision. The use of a visually 
338 identical placebo within the exact same treatment scheme is particularly important in noise 
339 anxiety and fear problems since a high level of placebo response has been reported 18. Subjects 
340 were observed for a single event only and thus were not considered to be at risk of excessive 
341 harm. The use of dexmedetomidine oral gel as a comparator would have had methodological 
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342 weaknesses as it requires additional handling and much more frequent dosing of the dogs, which 
343 would probably seriously reduce client compliance and necessitate a larger sample size. 
344 Consequently the use of placebo is ethically justified in this study.
345 In conclusion, noise phobia is a common, but under-recognized problem of dogs that has 
346 significant quality of life implications for the animal as well as its owner. Licensed treatment 
347 options are currently limited. In this study, we provide the first high quality evidence that 
348 imepitoin is very effective for controlling the fear and anxiety associated with noise phobia in the 
349 majority of dogs. Imepitoin was well tolerated and no serious adverse events were recorded. Even 
350 those owners that had dogs experiencing mild and generally transient adverse events such as 
351 ataxia, considered treatment beneficial based upon their willingness to continue treatment in most 
352 cases. Thus imepitoin represents a safe, simple and effective option for the control of fear and 
353 anxiety associated with noise phobia in dogs.
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415 Figure Legends
416 Figure 1: Study design and schedule of events.
417 Figure 2: Flow chart of exclusions from the analyzed populations. From all patients randomized 
418 into the study, patients who received at least one dose of study medication were included in the 
419 safety analysis. Cases were excluded from primary efficacy population (Full Analysis Set, FAS) 
420 if there were not sufficient data to evaluate the endpoints (e.g. termination of study prior to New 
421 Year’s Eve). Excluding cases with protocol deviations formed additional Per Protocol Sets (PPS). 
422 As per FDA guidance, also clinical sites with less than 4 evaluable cases had to be excluded, 
423 setting up the Per Protocol Population for FDA (US-PPP).
424 Figure 3: Histogram of owner's rating of overall treatment effect. There was a significantly 
425 higher proportion of owners reporting a good or excellent treatment effect in the imepitoin group 
426 compared to placebo (p < 0.0001) with an odds ratio of 4.689 (95%CI (2.79, 7.89)).
427 Figure 4: Evolution of anxiety score over time at baseline and on New Year’s Eve. Anxiety 
428 behaviors were significantly reduced under imepitoin treatment compared to placebo (p < 0.0001).
429 Figure 5: Ataxia was the most frequently reported adverse event in the imepitoin group. It was 
430 reported as occurring on the day of treatment initiation and resolving spontaneously under 
431 continuation of treatment in most cases on the same or the next day. Resolution decreased in an 
432 exponential fashion, with ~50% resolution within 24 hours after first drug administration. Data 
433 depicted as frequency of number of cases.
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434 Table 1: Histogram of owner’s rating of overall treatment effect on the anxiety behavior of dogs, 
435 assessed after the fireworks event. The grey marked scores indicate an insufficient treatment 
436 response. This information was not disclosed to owners.
437 Table 2: Score of  dog´s fear and anxiety signs on a detailed 16-item owner questionnaire
438 Table 3: Demographics and baseline Characteristics per group (based on all dogs treated with at 
439 least 1 dose of treatment; safety population). IVP: Investigational Veterinary Product (i.e. 
440 imepitoin; CP: Control Product (i.e. Placebo)
441 Table 4: Incidence of adverse events (based on all dogs treated with at least 1 dose of treatment; 
442 safety population)
443
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444 Table 1
Score Description
Excellent Effect The dog does not react to fireworks with anxious/fearful behaviour 
at all
Good Effect The dog’s reactions are mild and it can calm down 
Some Effect The dog is reacting somewhat less/milder than in previous year(s) 
without treatment but it cannot calm down
No Effect There is no reduction/change in the dog’s reactions compared to 
previous year(s) without treatment
Worse Effect The dog’s reaction to fireworks is stronger than in previous year(s) 
without treatment
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446 Table 2
Items (16) running around, drooling saliva, hiding, destructiveness, cowering, 
restlessness/pacing, aggressive behavior, “freezing to the spot”, 
barking/whining/howling, panting, 
vomiting/defecating/urinating/diarrhea, owner-seeking behavior, 
vigilance/scanning environment, bolts, shaking or trembling, and self-
harm
Score per item o 0  Not Present
o 1 
o 2
o 3
o 4
o 5  Excessive
447
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448
449 Table 3
Parameter Imepitoin (n=114) Placebo (n=124)
Age [years] Median (Min;Max) 7.0  (1; 13) 7.0  (1; 14)
Gender    Female
                Male
N (%)
N (%)
69 (60.5)
45 (39.5)
76 (61.3)
48 (38.7)
Breed1  
         Mixed Breed
         Other 
N (%)
N (%)
44 (38.6)
42 (36.8)
49 (39.5)
31 (25.0)
Body Weight (kg) Mean +/- SD 20.4 +/- 12.3 20.0 +/- 13.3
Total Lincoln Sound 
Sensitivity Scale
Median (Min;Max) 77.5 (32; 148) 74.5 (32;155)
450 1 Only breeds > 5 % are shown.  Other Breed is a rare breed or a breed not recognized by the Federation Cynologique 
451 Internationale (FCI) 
452
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453 Table 4
 Event Imepitoin(n=114)
Placebo
(n=124)
 All Adverse Events 55 13
 Ataxia 40 2
 Increased Appetite 21 1
 Lethargy 14 2
 Emesis 10 1
 Hyperactivity 7 1
 Somnolence 4 -
454 Note: Events with >2.5% frequency are shown. Number of animals affected (at least one event)
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Study design and schedule of events. 
247x83mm (150 x 150 DPI) 
Page 25 of 29 Journal of Veterinary Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Flow chart of exclusions from the analyzed populations. From all patients randomized into the study, 
patients who received at least one dose of study medication were included in the safety analysis. Cases were 
excluded from primary efficacy population (Full Analysis Set, FAS) if there were not sufficient data to 
evaluate the endpoints (e.g. termination of study prior to New Year’s Eve). Excluding cases with protocol 
deviations formed additional Per Protocol Sets (PPS). As per FDA guidance, also clinical sites with less than 4 
evaluable cases had to be excluded, setting up the Per Protocol Population for FDA (US-PPP). 
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Histogram of owner's rating of overall treatment effect. There was a significantly higher proportion of 
owners reporting a good or excellent treatment effect in the imepitoin group compared to placebo (p < 
0.0001) with an odds ratio of 4.689 (95%CI (2.79, 7.89)). 
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Evolution of anxiety score over time at baseline and on New Year’s Eve. Anxiety behaviors were significantly 
reduced under imepitoin treatment compared to placebo (p < 0.0001). 
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Ataxia was the most frequently reported adverse event in the imepitoin group. It was reported as occurring 
on the day of treatment initiation and resolving spontaneously under continuation of treatment in most 
cases on the same or the next day. Resolution decreased in an exponential fashion, with ~50% resolution 
within 24 hours after first drug administration. Data depicted as frequency of number of cases. 
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